SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (479)12/2/2019 2:29:44 PM
From: scaram(o)uche   of 684
 
A 15:1 reverse split and the Cantor agreement seem to have kept them in about the same position this year, with perhaps less dependence on older projects.

Market cap, 40m. Cash (9/30), 73m. Burn about 11m, so let's say current cash (assumes no Cantor activity) is about 63m. Current shareholder equity of ~ 90m.

Four projects worthy of pharma eyeballs?..... preclinical TAM (merTK, etc.), preclinical CD28xPD-L1, anti-kit (phase I), and an anti-CD 40 which may avoid toxicity observed with previous anti-CD40 efforts.

The CD28xPD-L1 bispecific is due in clinic 1H20.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News